C. Ponticelli and R. J. Glassock, Glomerular diseases: membranous nephropathy-a modern view, Clin J Am Soc Nephrol, vol.9, p.23813556, 2014.

L. H. Beck, R. G. Bonegio, G. Lambeau, D. M. Beck, D. W. Powell et al., M-type phospholipase A2 receptor as target antigen in primary membranous nephropathy, N Engl J Med, vol.361, pp.11-21, 2009.

A. Schieppati, L. Mosconi, A. Perna, G. Mecca, T. Bertani et al., Prognosis of untreated patients with primary membranous nephropathy, N Engl J Med, vol.329, pp.85-89, 1993.

N. Polanco, E. Gutiérrez, A. Covarsí, F. Ariza, A. Carreño et al., Spontaneous remission of nephrotic syndrome in primary membranous nephropathy, J Am Soc Nephrol, vol.21, pp.697-704, 2010.

J. V. Donadio, V. E. Torres, J. A. Velosa, R. D. Wagoner, K. E. Holley et al., Primary membranous nephropathy: the natural history of untreated patients, Kidney Int, vol.33, p.3367560, 1988.

C. Ponticelli, P. Zucchelli, P. Passerini, L. Cagnoli, B. Cesana et al., A randomized trial of methylprednisolone and chlorambucil in primary membranous nephropathy, N Engl J Med, vol.320, pp.8-13, 1989.

V. Jha, A. Ganguli, T. K. Saha, H. S. Kohli, K. Sud et al., A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by primary membranous nephropathy, J Am SocNephrol, vol.18, pp.1899-1904, 2007.

D. C. Cattran, C. Greenwood, S. Ritchie, K. Bernstein, D. N. Churchill et al., A controlled trial of cyclosporine in patients with progressive membranous nephropathy, Canadian Glomerulonephritis Study Group. Kidney Int, vol.47, p.7783410, 1995.

J. Van-den-brand, P. R. Van-dijk, J. M. Hofstra, and J. Wetzels, Cancer risk after cyclophosphamide treatment in primary membranous nephropathy, Clin J Am Soc Nephrol, vol.9, pp.1066-1073, 2014.

J. Radhakrishnan and D. C. Cattran, The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient, Kidney Int, vol.82, p.22895519, 2012.

H. Debiec and P. Ronco, PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy, N Engl J Med, vol.364, pp.689-690, 2011.

J. M. Hofstra, H. Debiec, C. D. Short, T. Pellé, R. Kleta et al., Antiphospholipase A2 receptor antibody titer and subclass in primary membranous nephropathy, J Am Soc Nephrol, vol.23, p.22956816, 2012.

E. Hoxha, I. Thiele, G. Zahner, U. Panzer, S. Harendza et al., Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, vol.25, p.24610926, 2014.

E. Hoxha, S. Harendza, H. Pinnschmidt, U. Panzer, and R. Stahl, PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system, PLoS ONE, vol.9, p.25313791, 2014.

D. Kanigicherla, J. Gummadova, E. A. Mckenzie, S. A. Roberts, S. Harris et al., Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with primary membranous nephropathy, Kidney Int, vol.83, pp.940-948, 2013.

E. Hoxha, S. Harendza, H. Pinnschmidt, U. Panzer, and R. Stahl, M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy, Clin J Am Soc Nephrol, vol.9, pp.1883-1890, 2014.

J. M. Hofstra, L. H. Beck, D. M. Beck, J. F. Wetzels, and D. J. Salant, Anti-phospholipase A? receptor antibodies correlate with clinical status in primary membranous nephropathy, Clin J Am Soc Nephrol, vol.6, p.21474589, 2011.

L. H. Beck, F. C. Fervenza, D. M. Beck, R. G. Bonegio, F. A. Malik et al., Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy, J Am SocNephrol, vol.22, pp.1543-1550, 2011.

H. Z. Qin, M. C. Zhang, W. B. Le, Q. Ren, D. C. Chen et al., Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy, J Am Soc Nephrol, 2016.

N. M. Tomas, L. H. Beck, C. Meyer-schwesinger, B. Seitz-polski, H. Ma et al., Thrombospondin type-1 domain-containing 7A in primary membranous nephropathy, N Engl J Med, vol.371, pp.2277-2287, 2014.

N. M. Tomas, E. Hoxha, A. T. Reinicke, L. Fester, U. Helmchen et al., Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy, J Clin Invest, vol.126, pp.2519-2532, 2016.

T. Stehlé, V. Audard, P. Ronco, and H. Debiec, Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy, Nephrol Dial Transplant, vol.30, 2015.

Q. Xie, Y. Li, J. Xue, Z. Xiong, L. Wang et al., Renal phospholipase A2 receptor in hepatitis B virusassociated membranous nephropathy, Am J Nephrol, vol.41, pp.345-353, 2015.

H. R. Dong, Y. Y. Wang, X. H. Cheng, G. Q. Wang, L. J. Sun et al., Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy, PLoS One, vol.11, 2016.

B. Svobodova, E. Honsova, P. Ronco, V. Tesar, and H. Debiec, Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy, Nephrology Dial Transplant, vol.28, pp.1839-1844, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00919114

A. P. Bech, J. M. Hofstra, . Brenchleype, and J. Wetzels, Association of anti-PLAR antibodies with outcomes after immunosuppressive therapy in primary membranous nephropathy, Clin J Am Soc Nephrol, vol.9, pp.1386-1392, 2014.

P. Ruggenenti, H. Debiec, B. Ruggiero, A. Chianca, T. Pellé et al., Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy, J Am Soc Nephrol, vol.26, pp.2545-2558, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02193793

K. Dahan, H. Debiec, E. Plaisier, M. Cachanado, A. Rousseau et al., Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up, J Am Soc Nephrol, vol.27, issue.2016
URL : https://hal.archives-ouvertes.fr/hal-01490466